This medication is a popular for its ability to inhibit the absorption of cholesterol in the small intestine.
Currently this drug is being teamed up with Simvastatin in a study to improve clinical treatment of cardiovascular events, non-fatal coronary events (such as heart attack), and non-fatal strokes
The answer to last weeks drug: Spiriva
http://www.cbc.ca/news/health/story/2010/09/20/asthma-spiriva-serevent-adults.html
Interestingly as well, Spiriva was in the news for a potential risk to COPD patients: